Randomized clinical trials in oncology: Principles and obstacles
- 1 November 1994
- Vol. 74 (S9) , 2614-2619
- https://doi.org/10.1002/1097-0142(19941101)74:9+<2620::aid-cncr2820741805>3.0.co;2-8
Abstract
Cancer clinical trials have two broad objectives: To identify promising treatments and to determine whether such treatments really do reduce morbidity and mortality. These two objectives generally require different types of clinical trials. The guiding principle of clinical trials is to ask an important question and get a reliable answer. Asking an important question generally means asking a question that has the potential for influencing medical practice, using a control treatment that is widely accepted, using an experimental treatment that is widely applicable, using an endpoint that is a direct measure of patient benefit, and studying a group of patients who are broadly representative. Getting a reliable answer also has many components, including randomized treatment assignment, adequate sample size, intent-to-treat analysis, and testing of prestated hypotheses on mature data. These components are discussed. Several recent developments in clinical trials methodology: interim monitoring boundaries, large simple trials, and metaanalysis, are highlighted here. Major obstacles to conducting randomized clinical trials are also described.Keywords
This publication has 10 references indexed in Scilit:
- A decade of progress in statistical methodology for clinical trialsStatistics in Medicine, 1991
- Approaches to Monitoring Clinical TrialsJNCI Journal of the National Cancer Institute, 1989
- Impact of multiple comparisons in randomized clinical trialsThe American Journal of Medicine, 1987
- Why do we need some large, simple randomized trials?Statistics in Medicine, 1984
- Analysis of survival by tumor response.Journal of Clinical Oncology, 1983
- Patient subsets and variation in therapeutic efficacy.British Journal of Clinical Pharmacology, 1982
- Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug ProjectNew England Journal of Medicine, 1980
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978
- Some Thoughts on Clinical Trials, Especially Problems of MultiplicityScience, 1977
- Randomized Clinical TrialsNew England Journal of Medicine, 1976